This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: Several lines of evidence indicate that a decrease in the CSF concentration of amyloid β42 (Aβ42) is a potential biomarker for incident Alzheimer disease. In contrast, studies on plasma Aβ1–40 and Aβ1–42 peptide levels have yielded contradictory results. Here, we explored the links between incident dementia and plasma Aβ1–40 and Aβ1–42 peptide concentrations in the prospective, population-based Three-City (3C) Study. We also assessed the association between plasma concentrations of truncated Aβ (Aβn-40 and Aβn-42) and the risk of dementia.
Methods: During a subsequent 4-year follow-up period, 257 individuals presented incident dementia from 8,414 participants, and a subcohort of 1,185 individuals without dementia was drawn as a control cohort. Plasma levels of Aβ1–40, Aβ1–42, Aβn-40, and Aβn-42 were measured using an xMAP-based assay technology. The association between plasma Aβ peptide levels and the risk of dementia was assessed using Cox proportional hazard models.
Results: Of the various Aβ variables analyzed, the Aβ1–42/Aβ1–40 and Aβn-42/Aβn-40 ratios presented the strongest association with the risk of dementia: people with a high Aβ1–42/Aβ1–40 or Aβn-42/Aβn-40 ratio had a lower risk of developing dementia. These associations were restricted to individuals diagnosed at 2 years of follow-up and the Aβn-42/Aβn-40 ratio was mainly associated with the risk of mixed/vascular dementia.
Conclusion: Plasma Aβ peptide concentrations and Aβ1–42/Aβ1–40 and Aβn-42/Aβn-40 ratios may be useful markers to indicate individuals susceptible to short-term risk of dementia.
Glossary
- Aβ=
- amyloid β;
- AD=
- Alzheimer disease;
- BMI=
- body mass index;
- CI=
- confidence interval;
- DSM-IV=
- Diagnostic and Statistical Manual of Mental Disorders, 4th edition;
- HDL=
- high-density lipoprotein;
- HR=
- hazard ratio;
- INSERM=
- Institut National de la Santé et de la Recherche Médicale;
- MCI=
- mild cognitive impairment;
- 3C=
- Three-City.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.